For immune microenvironment remodeling, myeloid cell reprogramming therapies targeting organ‐specific markers like TREM2 and in situ tumor niche vaccine platforms may activate CNS anti‐tumor immunity. The gene discussed is TREM2; the disease is neoplasm.